Natera Q2 Loss Narrows to $0.47, Revenue Jumps 38%; Raises 2026 Outlook
NTRA has more than doubled off its 52-week low of $135.75.
Summary
Natera delivered a strong Q2 with revenue up 38% to $752.8M, driven by a 57% surge in oncology test volumes. The net loss narrowed to $0.47 per share from $0.74 a year ago, and gross margin improved to 64.5%. Management raised full-year revenue guidance to $2.85B-$2.91B, above the prior range, while reaffirming margin and cash flow targets. This follows a series of positive regulatory and reimbursement wins, including FDA approval for Signatera in bladder cancer and expanded MolDx coverage for Prospera. The raised outlook signals accelerating commercial momentum across the testing portfolio.
At the time of this announcement, NTRA was trading at $308.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38B. The 52-week trading range was $135.75 to $288.04. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.